Relay Therapeutics Q3 net loss widens to $81.7 million, or $0.37 per share
Relay Therapeutics reported a third-quarter 2026 net loss of $81.7 million, or $0.37 per share, up from a net loss of $74.1 million, or $0.43 per share, a year earlier. The company had no revenue in the quarter and ended September 30, 2026 with $848.6 million in cash, cash equivalents and investments, which it says will fund operations into 2029.
Key points
- Q3 2026 net loss was $81.7 million ($0.37 per share), versus $74.1 million ($0.43 per share) in Q3 2025
- R&D expenses were $77.1 million, up from $68.3 million, partly due to non-recurring costs from terminating the One Kendall Square lease
- Cash, cash equivalents and investments were $848.6 million at September 30, 2026, down from $910.9 million at June 30, 2026
- Phase 3 ReDiscover-2 trial in second-line breast cancer is estimated to complete enrollment in mid-2027; ASH presentation scheduled for December 14, 2026
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.